companies must adhere to the following global regulations:

• USFDA 21 CFR Part 11: Governs electronic records and signatures for FDA-regulated products, including criteria for system validation, audit trails, user authentication, and signature linking.
• EMA Annex 11: Focuses on computerized systems used in GMP environments, requiring system validation, access control, data integrity safeguards, and record traceability.
• WHO GMP: Section 5.5 of WHO Technical Report Series (TRS 1019) outlines expectations for electronic systems handling GMP data.

Access a full regulatory comparison chart at Pharma Regulatory.

3. Requirements of 21 CFR Part 11

According to the USFDA, ERES-compliant systems must meet the following requirements:

• System Validation: Ensure accuracy, reliability, and consistent performance
• Audit Trails: Automatically generate secure, time-stamped records of changes
• User Authentication: Unique user IDs, secure passwords, and role-based access
• Electronic Signature Linking: Signatures must be linked to their respective records and non-editable
• Record Protection: Records must be retained and retrievable for the regulatory retention period
• Training and SOPs: Staff must be trained and SOPs must cover system use and compliance

These elements must be embedded into your validation plan, quality systems, and IT infrastructure.

4. System Validation and Risk-Based Approach

All electronic systems managing GxP data must be validated as per GAMP 5 principles. The validation lifecycle includes:

• User Requirement Specification (URS)
• Functional & Design Specifications (FS/DS)
• Installation Qualification (IQ)
• Operational Qualification (OQ)
• Performance Qualification (PQ)

Use a risk-based approach to determine validation depth and testing scope. High-risk systems (e.g., MES, LIMS, QMS) must undergo comprehensive validation with detailed test scripts, while low-risk systems (e.g., non-critical utilities) may require streamlined protocols.

Download validation templates and ERES checklists from Pharma Validation.

5. Managing Audit Trails and Data Integrity

Audit trails form the backbone of ERES compliance. They must be:

• Automatically generated
• Time-stamped and secure
• Linked to user ID and action performed
• Reviewable by authorized users

Systems should prevent deletion or modification of audit trails. Regular review of audit trail logs must be documented and performed during batch release or quality oversight.

For examples of ALCOA+ aligned audit trail SOPs, refer to Pharma SOP.

6. Implementing Electronic Signatures

Electronic signatures must be implemented with high security standards:

• Each signature must be uniquely linked to an individual user
• Signature authentication should require at least two components (e.g., ID and password)
• Signature must include printed name, date/time, and meaning (approval, review, etc.)
• System must prevent signature repudiation or unauthorized delegation

These signatures are legally binding when used in systems compliant with Part 11 or Annex 11.

7. Common Challenges and Remediation Strategies

Pharma companies often face issues like:

• Legacy systems without audit trail capability
• Shared login credentials compromising data integrity
• Incomplete validation documentation
• Inadequate SOPs on electronic records handling
• No periodic review of electronic logs

Address these by:

• Conducting a gap assessment against Part 11 and Annex 11
• Remediating system deficiencies through upgrades or replacements
• Developing robust SOPs for record handling and system use
• Training staff on data integrity, password hygiene, and ERES practices

Explore risk mitigation strategies at Pharma GMP.

8. Integration with Quality Management Systems

ERES compliance should not be siloed—it must be integrated into:

• QMS: Deviations, CAPAs, and change control must reflect electronic system management
• Training Programs: All users must be trained on system-specific compliance and signature protocols
• Document Control: Controlled documents must include e-record lifecycle control, including approval workflows and archival
• Audits: Internal audits must evaluate ERES compliance periodically

Periodic revalidation and backup testing should also be part of system lifecycle governance.

9. ERES in Cloud and SaaS Environments

With increased use of cloud-based systems and Software-as-a-Service (SaaS) platforms, ensuring compliance is more complex. Key points include:

• Vendor qualification and audit
• Data ownership and retrieval clauses in contracts
• Shared responsibility matrix (provider vs user)
• Audit trail access and data portability

Ensure that SaaS vendors support ERES functionalities and provide documentation for system validation.

10. Inspection Readiness and Regulatory Trends

Regulatory inspectors increasingly focus on:

• Review of audit trails during batch release
• System access control and user roles
• Uncontrolled use of USB/external storage
• System backdating or hidden deletions
• ERES SOPs and training records

Being inspection-ready means having clear policies, evidence of system validation, and trained users. For inspection mock audit tools, visit Stability Studies.

Conclusion

Electronic Records and Electronic Signatures (ERES) compliance is foundational to maintaining data integrity and meeting global regulatory expectations in modern pharmaceutical operations. A well-designed system, validated and governed by robust SOPs, can ensure accuracy, security, and audit readiness of all digital records.

By integrating ERES principles into your quality systems, training staff, and validating IT infrastructure, pharma companies can accelerate digital transformation while staying compliant and inspection-ready.

For templates, checklists, and validation tools, visit Pharma Validation and Pharma SOP.